Simian immunodeficiency virus

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Retrieved on: 
Monday, November 20, 2023
SIV, Food, Antigen, IND, Antibody, Arenavirus, FDA, The Mark of Gideon, Simian immunodeficiency virus, Vaccination, NPJ, Animal, HIV, Vaccine, LCMV, Gilead Sciences, Viral load

HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial.

Key Points: 
  • HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial.
  • The analyses published were conducted with a simian immunodeficiency virus (SIV) model, commonly used in a preclinical setting as a surrogate to HIV.
  • One vector is based on lymphocytic choriomeningitis virus (LCMV) as its arenaviral backbone; another vector is based on Pichinde virus (PICV).
  • HB-500 is one of two separate development programs in HOOKIPA’s collaboration and license agreement with Gilead.

Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, May 11, 2023
KRAS, SIV, Coalition, National Institute of Allergy and Infectious Diseases, Survival, RECIST, Congress, Lance, Patient, SLATE, Collaboration, Infection, Vaccination, Gritstone bio, National Cancer Institute, Research, Melinda French Gates, Lung cancer, ECCMID, Bill, CORAL, Conference, Vaccine, DNA, Gilead Sciences, Simian immunodeficiency virus, ESMO, CEPI, African, NSCLC, NAB, Immunotherapy, Messenger, CROI, Bill & Melinda Gates Foundation, European, NIAID, Epidemic, Circulating tumor DNA, CRC, HIV, Progression-free survival, SARS-CoV-2, Clinical trial, Coalition for Epidemic Preparedness Innovations, ChAdOx1, Fungal infection, Cryptocurrency, Pharmaceutical industry, Gritstone

EMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the first quarter ended March 31, 2023 and provided recent corporate and clinical updates.

Key Points: 
  • We recently observed durable neutralizing antibody titers at 6 months following samRNA vaccination in over 100 vaccine-naïve subjects treated within our CORAL-CEPI trial, where interim results were presented at ECCMID 2023.
  • As of May 10, 2023, the company had randomized 71 of the initially planned 80 total patients.
  • Both datasets were presented at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023).
  • In February 2023, results from a preclinical study conducted in collaboration with Gilead were presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2023.

Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, March 9, 2023
SIV, Vaccine, Cancer, HIV, Neoplasm, Trifluridine/tipiracil, United States Patent and Trademark Office, MOS, Clinical trial, NCI, 1836 U.S. Patent Office fire, KRAS, ESMO, Fungal infection, Infection, CRC, National Cancer Institute, Simian immunodeficiency virus, Conference, Collaboration, CROI, Research, NIAID, Patient, FDA, DNA, Circulating tumor DNA, RECIST, Patent, Gilead Sciences, OS, MRR, Regorafenib, Progression-free survival, Therapy, ChAdOx1, NSCLC, Messenger, Immunotherapy, CORAL, SLATE, Pharmaceutical industry, Cryptocurrency, Nature Medicine, Gritstone

-- Gritstone to host conference call today at 4:30pm ET --

Key Points: 
  • -- In August 2022, interim results from the Phase 1/2 trial of GRANITE, Gritstone’s individualized neoantigen vaccine for solid tumor cancers, were published in Nature Medicine ( here ).
  • -- In August 2022, Gritstone reported 6-month neutralizing antibody data from the first two cohorts of its CORAL-BOOST trial.
  • -- In October 2022, Gritstone shared interim positive results from the ongoing Phase 1 CORAL-BOOST and CORAL-CEPI studies at a Company-sponsored webinar .
  • Collaboration, license, and grant revenues were $19.9 million for the year ended December 31, 2022, compared to $48.2 million for the prior year.

Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies

Retrieved on: 
Tuesday, February 21, 2023
Research, Infectious Diseases, Hospitals, FDA, Clinical Trials, Biotechnology, AIDS, Pharmaceutical, Health, Science, University of California, San Francisco, HIV/AIDS research, HIV, University, MD, TITAN, Simian immunodeficiency virus, Fungal infection, Infection, ART, SIV, Gilead Sciences, ChAdOx1, Hook effect, Conference, Canadian Foundation for AIDS Research, Aarhus University, Vaccine, CROI, Pharmaceutical industry

These latest findings represent an ongoing multi-pronged approach in Gilead’s HIV cure research program.

Key Points: 
  • These latest findings represent an ongoing multi-pronged approach in Gilead’s HIV cure research program.
  • Findings from the HIV cure research program include results from three studies evaluating strategies to maintain virologic control in the absence of ART.
  • “Gilead will continue exploring novel combination strategies in our pursuit to help end the HIV epidemic for everyone, everywhere.”
    Curing HIV remains the ultimate aspiration of Gilead’s HIV research and development efforts.
  • Gilead has a comprehensive cure research and development program that is advancing with speed and conviction.

Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone Symposium

Retrieved on: 
Friday, June 3, 2022
Program, Immunodeficiency, Lung, Simian immunodeficiency virus, Primate, Cancer, Blood, Therapy, Prostate cancer, Keystone, Infection, Lymphocytic choriomeningitis, CD8, GLOBE, LCMV, HBV, Arenavirus, Gilead Sciences, NASDAQ, AIDS, HIV, KRAS, SIV, Lymph, Pharmaceutical industry, Vaccine

These data presented at the Keystone Symposium: Progress in Vaccine Development for Infectious Disease in Breckenridge, Colorado highlight robust and high-quality immune responses following administration of replicating arenaviral therapeutic vaccines.

Key Points: 
  • These data presented at the Keystone Symposium: Progress in Vaccine Development for Infectious Disease in Breckenridge, Colorado highlight robust and high-quality immune responses following administration of replicating arenaviral therapeutic vaccines.
  • These preclinical data highlight the potential of our novel arenaviral platform to deliver new options to treat HIV, said Joern Aldag, Chief Executive Officer at HOOKIPA.
  • Together, the preclinical data on the HIV arenaviral program support clinical development as a component of a potential HIV therapeutic.
  • Preclinical data in a separate poster presentation (poster 1019) showed the breadth and quality of the immune response with intramuscular administration of arenaviral therapeutic vaccines.

CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species”

Retrieved on: 
Tuesday, April 12, 2022
CEO, XV, Clinical trial, Northwestern Health Sciences University, HIV, U.S. Securities and Exchange Commission, Security (finance), Risk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SHIV, Food, Compliance, GLOBE, CCR5, Patient, Immunoglobulin G, 100,000, Form 10-K, Simian immunodeficiency virus, Infection, PLOS Pathogens, Oregon Health & Science University, Company, OTCQB, Vaccine, Social conditions in Honduras, Forward-looking statement, Optimism, Mab, Partnership, FDA, Cancer, Pharmaceutical industry, Leronlimab

The study followed five HIV+ human participants who, after successfully transitioning to once weekly subcutaneous leronlimab, halted their previous daily oral antiretroviral therapy regimens.

Key Points: 
  • The study followed five HIV+ human participants who, after successfully transitioning to once weekly subcutaneous leronlimab, halted their previous daily oral antiretroviral therapy regimens.
  • These five participants came from an extension study, consisting of patients who were virologically suppressed in a prior study of leronlimab.
  • All five long-term participants successfully maintained HIV suppression via leronlimab monotherapy for over seven years, with no evidence of viral escape.
  • To monitor the anatomical penetrance of leronlimab, rhesus macaques acutely infected with simian human immunodeficiency virus (SHIV) were treated with high intravenous doses of leronlimab for 12 weeks.

Urgent Rescue Mission for Young Monkey Kept Illegally as "Pet" in Chicago: "Willis" the Vervet Begins New Life at Born Free USA's Texas Sanctuary.

Retrieved on: 
Monday, November 15, 2021
Control, Safety, Primate, Captive Primate Safety Act, Viral hepatitis, Measles, HIV, Mark (given name), CACC, Lincoln Park Zoo, Language program director, Attack, PETS, Animal, SIV, Human, Respect, Internet, Yellow fever, Monkeyland Primate Sanctuary, Laboratory, Bitten, Born Free, B, Injury, Simian immunodeficiency virus, Time, Life, Safe Humane Chicago, Risk, Hunting

This rescue operation took up the time and resources of taxpayer funded officials, our nonprofit organization, and private citizens.

Key Points: 
  • This rescue operation took up the time and resources of taxpayer funded officials, our nonprofit organization, and private citizens.
  • All this to fix a problem created by someone who was cruelly and illegally keeping little Willis as a "pet."
  • Although no one knows how many, it is estimated there are thousands of primates kept as "pets" in U.S. homes.
  • Rush says, "Despite the fact that keeping a pet monkey is illegal in Illinois, Willis the vervet monkey slipped through the cracks.

New Report Brings Together Experts to Call for Immediate Ban on Pet Monkeys and Apes

Retrieved on: 
Tuesday, October 12, 2021
People, B virus, Measles, Captive Primate Safety Act, Simian immunodeficiency virus, Public health, Risk, PTSD, Law enforcement, Animal, Respect, Born Free, PETS, Time, Viral hepatitis, Safety, HIV, Human, B, SIV, Laboratory, Monkeyland Primate Sanctuary, News, Yellow fever, Congress, Primate, Legislation, Language program director

Not only does the private keeping of monkeys and apes pose a significant risk of injury and disease spread to humans, it has a lifetime impact on its animal victims.

Key Points: 
  • Not only does the private keeping of monkeys and apes pose a significant risk of injury and disease spread to humans, it has a lifetime impact on its animal victims.
  • All primates are profoundly social, complex individuals whose needs can never be met when kept in private homes.
  • Harrison says:
    "There are no schools, no police academy, fire school, or animal control teaching you how to handle primates.
  • We oppose the exploitation of wild animals in captivity and campaign to keep them where they belongin the wild.

Born Free USA Rescues Third "Pet" Monkey in Three Months, Calls for Ban on Pet Primates

Retrieved on: 
Monday, September 13, 2021
Born Free, Monkeyland Primate Sanctuary, PETS, Congress, Captive Primate Safety Act, Primate, Yellow fever, SIV, Animal, HIV, Viral hepatitis, Commerce, Freedom, Laboratory, News, B virus, Legislation, Respect, Death, Simian immunodeficiency virus, B, University, Human, Measles, Chimpanzee, Life, Hunting

COTULLA, Texas, Sept. 13, 2021 /PRNewswire/ --Leading animal welfare nonprofit, Born Free USA , welcomed a new monkey to its primate sanctuary in South Texas last week.

Key Points: 
  • COTULLA, Texas, Sept. 13, 2021 /PRNewswire/ --Leading animal welfare nonprofit, Born Free USA , welcomed a new monkey to its primate sanctuary in South Texas last week.
  • He is the third pet monkey the nonprofit has rescued in as many months.
  • Says Dr. Liz Tyson, Born Free USA Programs Director and head of the primate sanctuary, "Maliki is one of the lucky ones.
  • Born Free USA's Primate Sanctuary is the largest in the United States and provides a permanent home for primates rehomed from laboratories or rescued from zoos and private ownership.

CytoDyn’s Leronlimab Prevents Transmission of SHIV in Macaque Study

Retrieved on: 
Tuesday, July 7, 2020
Viruses, Lentiviruses, Virology, Contents, Animal virology, Sexually transmitted diseases and infections, Simian immunodeficiency virus, HIV/AIDS, HIV, HIV vaccine

The study evaluated the impact of a macaque-equivalent dose of either 350 mg (once weekly) or 700 mg (bi-monthly) leronlimab on acquisition of infection in a total of 18 animals, and found that the equivalent 700 mg bi-monthly leronlimab dose completely prevented rectal transmission of Simian-Human Immunodeficiency Virus (SHIV) in macaques.

Key Points: 
  • The study evaluated the impact of a macaque-equivalent dose of either 350 mg (once weekly) or 700 mg (bi-monthly) leronlimab on acquisition of infection in a total of 18 animals, and found that the equivalent 700 mg bi-monthly leronlimab dose completely prevented rectal transmission of Simian-Human Immunodeficiency Virus (SHIV) in macaques.
  • Coupled with its safety profile, leronlimab could offer a much needed simple and long-lasting preventative treatment option for people at risk of HIV infection, concluded Dr. Pourhassan.
  • The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases.
  • Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans.